Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
729369
Reference Type
Journal Article
Subtype
Review
Title
Nonalcoholic fatty liver disease
Author(s)
Adams, LA; Lindor, KD
Year
2007
Is Peer Reviewed?
1
Journal
Annals of Epidemiology
ISSN:
1047-2797
EISSN:
1873-2585
Volume
17
Issue
11
Page Numbers
863-869
Language
English
PMID
17728149
DOI
10.1016/j.annepidem.2007.05.013
Abstract
Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis not associated with a significant intake of ethanol. Insulin resistance is central to the pathogenesis of NAFLD; thus obesity, diabetes, and the metabolic syndrome are frequently associated with the disease. Consequently, as these metabolic conditions emerge as major health problems in Western society, it is now recognized that NAFLD is the most common chronic liver condition in the Western world. NAFLD is generally asymptomatic, although a minority of patients may present with evidence of progressive liver injury with complications of cirrhosis, liver failure, and hepatocellular carcinoma. Despite being common and potentially serious, relatively little is known about the natural history or prognostic significance of NAFLD. Although diabetes, obesity, and age are recognized risk factors for advanced liver disease, other significant factors leading to progressive liver injury remain to be identified. The treatment of NAFLD focuses upon modifying metabolic risk factors. Insulin-sensitizing and hepatoprotective drugs have been subjected to study trials, but as yet, no agent has conclusively been demonstrated to prevent disease progression. Management is further complicated by the inability to predict which patients will develop liver-related morbidity and thus benefit from treatment.
Tags
IRIS
•
Trichloroethylene (TCE) (Final, 2011)
All References
Liver Issues
OPPT REs
•
OPPT_Trichloroethylene (TCE)_C. Engineering
Total – title/abstract screening
Off topic
•
OPPT_Trichloroethylene (TCE)_D. Exposure
Total – title/abstract screening
Off topic
•
OPPT_Trichloroethylene (TCE)_E. Fate
Total – title/abstract screening
Off topic
•
OPPT_Trichloroethylene (TCE)_F. Human Health
Total – title/abstract screening
Off topic
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity